Journal
LUNG CANCER
Volume 64, Issue 2, Pages 211-218Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2008.08.013
Keywords
Peritoneal mesothelioma; Pemetrexed; Platinum; Cisplatin; Carboplatin; Compassionate-use program; Expanded Access Program (EAP)
Categories
Funding
- Eli Lilly and Company
Ask authors/readers for more resources
Aim: Peritoneal mesothelioma (PM) has rarely been studied. The Expanded Access Program (EAP) provided access to 109 patients with PM. Methods: This was a nonrandomized, open-label study conducted in chemo-naive or previously treated patients with PM not amenable to curative surgery. Patients received pemetrexed (PEM) 500 mg/m(2) alone or with cisplatin (CIS) 75 mg/m(2) or carboplatin (CARBO) AUC 5 every 21 days, supplemented with standard vitamin B-12, folate, and dexamethasone. Results: Response rates (95% CI) for PEM, PEM/CIS, and PEM/CARBO were 12.5% (3.5, 29.0), 20.0% (7.7, 38.6), and 24.1% (10.3, 43.5), respectively. Median survival for PEM was 10.3 months. One-year survival rates for PEM/CIS and PEM were 57.4% (95% Cl: 10.3, 100) and 41.5% (95% Cl: 4.6, 78.4), respectively, and were not available for PEM/CARBO. Anemia was the most common serious adverse event (6.4%). Neutropenia (34.6%) was the most frequent CTC grade 3 or 4 toxicity reported. Concluding statement: PEM with or without a platinum agent was both active and well tolerated in patients with peritoneal mesothelioma. (C) 2008 Published by Elsevier Ireland Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available